TriLink BioTechnologies said this week that it has signed a licensing agreement with Biofortuna for use of its CleanAmp dNTPs in Biofortuna's freeze-dried in vitro diagnostic PCR kits.

Biofortuna will use the dNTPs for a line of human leukocyte antigen diagnostic kits it is developing for the transplantation, blood grouping, disease identification, and pharmacogenetic markets. The company is targeting its first product for the sequence-specific primer transplantation market.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.